Title:
CAMPTOTHECIN PRODRUG AND PHARMACEUTICAL COMPOSITION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/232048
Kind Code:
A1
Abstract:
Disclosed are a compound of general formula (I), and a stereoisomer and a cis-trans isomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 are as defined in the present disclosure.
Inventors:
HONG ZHANGYONG (CN)
ZHANG HESHENG (CN)
ZENG GUANGHUAI (CN)
ZHANG HESHENG (CN)
ZENG GUANGHUAI (CN)
Application Number:
PCT/CN2023/097277
Publication Date:
December 07, 2023
Filing Date:
May 30, 2023
Export Citation:
Assignee:
TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN)
International Classes:
C07H15/203; A61K31/706; A61K38/14; A61P35/00
Domestic Patent References:
| WO2011066418A1 | 2011-06-03 |
Foreign References:
| CN111362990A | 2020-07-03 |
Other References:
PRIJOVICH ZELJKO M., BURNOUF PIERRE-ALAIN, CHOU HUA-CHENG, HUANG PING-TING, CHEN KAI-CHUAN, CHENG TIAN-LU, LEU YU-LIN, ROFFLER STE: "Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation", MOLECULAR PHARMACEUTICS, AMERICAN CHEMICAL SOCIETY, US, vol. 13, no. 4, 4 April 2016 (2016-04-04), US , pages 1242 - 1250, XP093115271, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.5b00771
LEU, YU-LING ET AL.: "Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 6, 5 March 2008 (2008-03-05), pages 1740 - 1746, XP002497877, DOI: 10.1021/jm701151c
LEU, YU-LING ET AL.: "Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 6, 5 March 2008 (2008-03-05), pages 1740 - 1746, XP002497877, DOI: 10.1021/jm701151c
Attorney, Agent or Firm:
BEIJING HARTEND INTELLECTUAL PROPERTY AGENCY CO., LTD. (CN)
Download PDF: